Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.

ABSTRACT:

Background

Bevacizumab, a monoclonal antibody against soluble VEGFA, is an approved and commonly administered anti-angiogenic drug in patients with metastasized colorectal cancer (mCRC). The survival benefit of anti-VEGF therapy in mCRC patients is limited to a few months, and acquired resistance mechanisms are largely unknown. Here, we employed whole-genome sequencing of plasma DNA to evaluate the tumor genome of patients undergoing treatment with bevacizumab to determine novel aberrations associated with resistance.

Methods

Using longitudinal plasma analyses, we studied the evolution of tumor genomes in a mCRC cohort (n = 150) and conducted analyses of CRC cases from The Cancer Genome Atlas (TCGA) database (n = 619) to identify associations between genomic aberrations and

SUBMITTER: Zhou Q 

PROVIDER: S-EPMC7036260 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature